Comparative Pharmacology
Head-to-head clinical analysis: DIENESTROL versus LYGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIENESTROL versus LYGEN.
DIENESTROL vs LYGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to effects similar to endogenous estrogens.
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
0.1 to 0.5 mg orally once daily for estrogen replacement therapy; 0.5 to 1.0 mg orally once daily for prostatic carcinoma.
For adults, administer 500 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 24-48 hours, longer with hepatic impairment.
Clinical Note
moderateDienestrol + Etoricoxib
"Dienestrol may increase the thrombogenic activities of Etoricoxib."
Clinical Note
moderateDienestrol + Parecoxib
"Dienestrol may increase the thrombogenic activities of Parecoxib."
Clinical Note
moderateDienestrol + Voriconazole
"The metabolism of Voriconazole can be decreased when combined with Dienestrol."
Clinical Note
moderateDienestrol + Lumiracoxib
"Dienestrol may increase the thrombogenic activities of Lumiracoxib."
12 hours; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (40-60% as glucuronide conjugates) and biliary/fecal (30-50% with enterohepatic recycling).
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
Estrogen
Estrogen